date:Aug 06, 2012
company, based in Tarrytown, New York, has a promising array of other drugs in development with Sanofi to treat cancer, cholesterol and inflammatory diseases.
Regeneron shares, which rose 1.1 percent to $137.95 on Friday, have soared 250 percent since the FDA approved Eylea on November 18.
Regeneron research chief George Yancopoulos said anti-angiogenesis drugs, like Zaltrap and Avastin, have not been able to slow down tumor growth nearly as well as researchers had originally hoped.
We thought